Business
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
LEXINGTON, Mass., January 21, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to increasing physician-initiated interest regarding authorized access to the investigational immunotherapy combination botensilimab plus balstilimab (BOT+BAL).
About this update from Agenus Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1694,"height":353,"url":"https://media.zenfs.com/en/business-wire.com/f6870ff8d850a25f67fc3c294c118ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UuUXjWybUEwmPTI9aRq9cQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f6870ff8d850a25f67fc3c294c118ecc","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/UExav2nvCfuuGzFHrbp4kA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f6870ff8d850a25f67fc3c294c118ecc","width":1200,"height":250}},"lazy":false},{"type":"text","content":"Medical Affairs scale-up supports France’s multi-tumor AAC access framework and expanding paid named-patient programs requests","length":126,"tagName":"p"},{"type":"text","content":"LEXINGTON, Mass., January 21, 2026--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to increasing physician-initiated interest regarding authorized access to the investigational immunotherapy combination botensilimab plus balstilimab (BOT+BAL).","length":406,"tagName":"p"},{"type":"text","content":"The expansion reflects increasing interest from treating oncologists worldwide seeking access to BOT+BAL for patients with advanced solid tumors through regulatory-authorized early access pathways, including France’s Authorisation d’Accès Compassionnel (AAC) framework and paid named patient programs (NPPs) where permitted. This interest follows a series of recent scientific milestones, including peer-reviewed publications, clinical data presentations at major international scientific meetings and the recent expansion of reimbursed compassionate access for BOT+BAL under France’s AAC framework that now includes three tumor types.","length":635,"tagName":"p"},{"type":"text","content":"This scientific and regulatory validation has translated into real-world physician action. Patients have already been treated with BOT + BAL through regulatory-authorized paid named patient programs in multiple countries across South and Central America and Europe, including the United King...